Polycystic kidney disease (ADPKD)

Every kidney tubule is lined by cells that sense flow through hair-like cilia. In ADPKD, variants in the PKD1 or PKD2 genes disable parts of that sensing machinery (the proteins polycystin-1 and -2), and scattered tubule cells respond by proliferating and secreting fluid, ballooning segments of tubule into kidney cysts. Each cyst is microscopic at birth; over decades they multiply into thousands and grow relentlessly — kidneys that normally weigh a few hundred grams can reach many times that size, among the largest organs pathology museums hold. Function falls late and deceptively: for years, unaffected tissue compensates, holding eGFR near normal while total kidney volume — the true disease clock — climbs; when decline begins, typically in the thirties to fifties, it proceeds at a broadly steady individual pace towards kidney failure.

ADPKD is common as inherited diseases go — of the order of one in one-to-two-and-a-half thousand births — and accounts for a meaningful share of dialysis and transplant populations worldwide, with none of the geographic concentration of thalassaemia: it appears in every ancestry. The gene involved sets the tempo more than anything else known: PKD1 variants (the large majority) run harder, with kidney failure typically arriving in the fifties; PKD2 runs a decade or two gentler, sometimes never reaching failure at all; truncating variants outpace missense ones. Around one case in ten arises from a new mutation, so absence of family history excludes nothing.

Two more orientation points. ADPKD is a systemic disease wearing a kidney label: cysts commonly grow in the liver (usually harmlessly), and blood vessel walls share the defect — the basis of the intracranial aneurysm story handled honestly in the complications section. And it must be separated from its rare severe cousin, autosomal recessive PKD (ARPKD), a disease of infancy and childhood with different genetics and course, and from the various benign simple cysts of ordinary ageing kidneys — distinctions imaging criteria and, increasingly, genetic testing settle cleanly.

Because ADPKD spans decades, its care model is longitudinal by design: a nephrology relationship that may begin with a normal eGFR and a scan in one’s twenties and run, in the same notes, to a transplant in one’s fifties. That horizon changes how decisions feel — almost nothing in this disease is urgent, and almost everything rewards being early — and it makes the patient the archive: families who keep their own copies of volumes, slopes and blood pressures move between clinics, cities and countries without losing the thread the disease is best managed by.

ADPKD is usually silent through the first decades — many people learn of it not from symptoms but from family screening or an incidental scan. When symptoms come, the earliest are usually pressure and pain: a dull ache or fullness in the flank or back as kidneys enlarge, episodes of sharper pain when a cyst bleeds into itself (alarming, self-limiting, classically leaving cola-coloured urine), or the distinct colicky pain of kidney stones, which form more often in cystic kidneys. Blood in the urine — visible or on dipstick — follows cyst bleeds and stones. Urinary tract infections are commoner and occasionally settle INTO a cyst, causing fever with focal flank pain that needs longer, cyst-penetrating antibiotic courses.

High blood pressure is the great early sign that does not feel like one: it typically arrives in the twenties or thirties — before any kidney function is measurably lost — and is often the diagnosis’s first clue in an unscreened person. Its early treatment is also the oldest and best-proven protective intervention in the disease. As kidneys and often liver enlarge over years, bulk itself becomes a symptom: early fullness at meals, reflux, a visibly protuberant abdomen, clothes that fit strangely — burdens patients report as more real than clinicians historically credited. The late symptoms are those of failing kidneys anywhere: fatigue, nausea, itching, cramps, breathlessness and swelling, arriving in the same order this platform’s other kidney pages describe.

The symptom-to-action translation: anyone with a PKD parent deserves blood pressure checks from young adulthood regardless of feeling well; flank pain with fever needs same-day review; and the sudden, worst-ever headache belongs in the red flags below — rare, but this disease’s one true neurological emergency.

Blood in the urine deserves its calibration too, because it recurs across PKD lives: a cyst bleed after exertion typically produces painless or ache-associated dark urine that clears over days with rest and fluids — alarming, familiar, benign. The variants that break that pattern and warrant same-week review: clots, fever alongside, bleeding lasting beyond a week, or bleeding with the colicky pain of a stone. Most patients learn their own bleed pattern; new departures from it are the signal.

ADPKD is caused, in the great majority, by inherited variants in PKD1 (chromosome 16, ~75–80% of typed cases, the severe end) or PKD2 (chromosome 4, ~15%, the gentler end), with a small remainder from rarer genes (GANAB, DNAJB11 and others) or never typed. Inheritance is autosomal dominant: one variant suffices, each child of an affected parent has a 50% chance, men and women equally, and the disease does not skip generations — though its variable tempo means a mildly affected parent can be diagnosed after their more severely affected child. Roughly 10% of patients carry a new (de novo) mutation, standing first in their family line.

Why do cysts appear patchily, in a minority of tubules, when every cell carries the variant? The prevailing two-hit model: a tubule cell cysts when its second, previously normal copy of the gene is lost to a random somatic event — making cyst formation a lifetime accumulation of molecular accidents, which fits the disease’s relentless, age-linked arithmetic and explains within-family variation beyond the gene itself. Modifier genes, the specific variant’s severity, and environment (blood pressure above all; there are signals for hydration and caffeine worth the modest advice they receive) tune the pace.

What does NOT cause it deserves a line for the newly diagnosed: nothing the patient ate, did, or failed to do — and nothing their parent chose. And for family planning, the options conversation exists and is worth having early: preimplantation genetic testing after IVF is available in many countries for couples who wish to interrupt transmission, prenatal testing likewise, and genetic counselling — not this page — is where those weighty, personal choices belong.

Gene-negative families exist and deserve the sentence: in a small share of clinically typical ADPKD, current panels find no causal variant — biology not yet catalogued rather than absent — and care proceeds on imaging and family history exactly as before. Conversely, variant-of-uncertain-significance results are common enough that no major decision (donation above all) should rest on a genetic report without a specialist’s interpretation of it.

For having ADPKD, the risk factor is parentage: an affected parent means a coin-flip per child; no ancestry, lifestyle or exposure changes that arithmetic, and one in ten cases starts fresh with a new mutation. Screening of at-risk relatives is a considered choice rather than a reflex — imaging in the twenties or thirties answers most questions cheaply, but a negative scan under thirty does not fully exclude, and some young adults defer testing for insurance, career or psychological reasons: a legitimate decision that genetic counselling frames properly.

For progressing quickly — the question that now decides drug eligibility — the established markers are: the genotype (PKD1, especially truncating variants); early-onset hypertension or urological events (bleeds, stones, infections before 35); male sex, modestly; and above all the kidneys’ measured trajectory — total kidney volume for age (the Mayo imaging classification’s height-adjusted classes 1C–1E mark the fast lane) and observed eGFR slope. Family history of kidney failure before ~58 points the same way (the PROPKD score formalises several of these). These markers matter practically: they are the entry ticket to tolvaptan and to trials, and they justify the closer monitoring that faster disease earns.

Caffeine’s honest paragraph: older cell studies raised concern, human data have largely reassured, and current advice has settled on moderation rather than prohibition — a normal coffee habit is not a demonstrated accelerant. It earns its mention mostly as an example of PKD’s internet problem: decades-old laboratory findings circulating as dietary law. The evidence-graded sources below are the antidote.

ADPKD staging is unusual: for decades the standard eGFR ladder (this platform’s diabetic kidney page walks it) under-describes the disease, because compensation hides loss. Modern tracking therefore reads two clocks — kidney VOLUME early, eGFR late — and the Mayo classification turns the first into risk classes.

Diagnosis in someone with a family history is usually made by ultrasound against validated age-banded criteria — enough cysts for age (for example, three or more across both kidneys between 15 and 39, rising thereafter) confirms; strikingly few by 40 makes ADPKD very unlikely. Without family history, bilateral cystic enlargement plus supporting features (liver cysts prominently) builds the case. Genetic testing — PKD1/PKD2 panels — is not needed for most diagnoses but earns its place where imaging is equivocal, where a young relative wants certainty (especially as a potential kidney DONOR, where excluding carrier status is mandatory), for family-planning decisions, and increasingly for prognosis, since genotype stratifies pace.

The monitoring file then runs on the two clocks. MRI (or CT) measures total kidney volume, height-adjusts it, and places the patient on the Mayo classification — the single best early predictor and the practical gatekeeper for tolvaptan; it is repeated at intervals of one to a few years depending on class. Standard kidney tracking joins from the start and dominates later: creatinine/eGFR with its slope watched more than its level, urine checks, and — relentlessly — blood pressure, including home readings, since control from youth is the disease’s oldest proven protection. Complication-driven imaging fills in as needed: CT for suspected stones; MRI/PET approaches for the occasionally elusive infected cyst; liver imaging when bulk symptoms suggest hepatic cysts are contributing.

One screening question deserves its structured answer: intracranial aneurysm imaging (MR angiography) is NOT universal — it is offered to those with a family history of aneurysm or brain haemorrhage, warning symptoms, high-risk occupations, or high anxiety, per guidelines, because aneurysms cluster in families and unselected screening generates more worry than benefit. And at stage G4, the file pivots to transplant preparation — the work-up this platform’s destination pages describe, with PKD’s additions noted in the pathway section below.

Urine and blood surveillance carry two PKD-specific readings worth knowing. Modest proteinuria is common; HEAVY proteinuria is not, and prompts a search for a second kidney disease riding along. And eGFR’s long normal plateau means a young adult’s normal result is expected, not exonerating — volume, not filtration, tells the early truth, which is why the MRI joined the standard toolkit at all.

The values that structure an ADPKD clinic letter.

The renal complications are the disease’s texture: cyst haemorrhage (painful, alarming, almost always self-limiting with rest and fluids); kidney stones in perhaps a quarter of patients, managed as stones are everywhere with anatomy-adapted technique; urinary infections, with the special case of the infected cyst — fever plus focal pain, needing prolonged cyst-penetrating antibiotics and occasionally drainage; chronic pain from organ bulk in advanced disease, deserving a proper ladder from simple measures through cyst aspiration/sclerotherapy to, rarely, surgical options; and, ultimately, kidney failure with all its systemic company (anaemia, bone-mineral disease — the standard CKD complications this platform details elsewhere).

Beyond the kidneys: liver cysts are near-universal by middle age and usually silent; a minority — predominantly women — develop severe polycystic liver disease whose problem is bulk, not function (liver tests stay normal), managed from observation through drainage to, in extreme cases, liver resection or transplantation. Heart valve findings (mitral prolapse) are commoner than background and rarely matter; diverticular disease and hernias associate modestly.

The vascular paragraph, honestly: intracranial aneurysms occur in roughly 9–12% of ADPKD patients versus ~2–3% of the general population, cluster strongly in families (risk roughly doubles with an affected relative), and their rupture — subarachnoid haemorrhage — is the disease’s one catastrophic non-renal event. The measured response guidelines codify: screening MRA for the defined higher-risk groups (family history of aneurysm/haemorrhage, prior events, warning symptoms, certain occupations, patient preference after counselling), not for everyone; found aneurysms are managed by neurosurgical teams by size and site, many simply watched; and every patient learns the thunderclap-headache rule from the red-flag box above. Fear calibrated to numbers — most patients will never have an aneurysm event — is the aim of that paragraph, not reassurance or alarm.

Pain deserves its own management note, because it is the symptom patients report clinicians underrate. Chronic flank and back pain in enlarged kidneys has a real toolkit: positional and physiotherapy approaches first; analgesia that respects kidneys (paracetamol-based, NSAIDs avoided); cyst aspiration with sclerotherapy for identifiable culprit cysts; and, for refractory cases at specialist centres, denervation techniques or surgical options. “Live with it” is not the end of that list, and asking to walk the ladder is legitimate at any stage.

ADPKD cannot be prevented in the conceived individual — the variant is present from the start — so prevention means slowing progression and pre-empting complications, and the evidence has real content. Blood pressure control is the foundation: treatment from young adulthood, typically built on ACE inhibitors or ARBs, with the HALT-PKD trials showing that in young patients with early disease, tighter-than-standard targets slowed kidney growth — the basis for the stricter goals many clinics now set for the fast lane. Hydration earns its modest place mechanistically (vasopressin drives cyst growth; drinking enough to keep urine pale suppresses it) — sensible, cheap, unproven as monotherapy; caffeine moderation follows similar low-stakes logic. Dietary sodium restriction supports the blood pressure work and associated with slower growth in trial analyses; weight management likewise. NSAIDs, dehydration and contrast dye join the standing avoid-when-possible list of every CKD page; smoking cessation needs no PKD-specific argument.

Complication pre-emption is concrete: prompt culture-guided treatment of urinary infections before they seed cysts; stone prevention through fluids and stone-clinic advice after a first event; the aneurysm screening conversation for those in defined risk groups; and — the item families most often miss — pre-emptive TRANSPLANT planning from stage G4, so that failure, when it comes, meets a prepared candidate with a possible living donor already evaluated, rather than an emergency dialysis start. Finally, prevention across generations: preimplantation genetic testing exists, works, and is a personal choice that deserves a genetic counsellor’s room rather than a webpage’s paragraph — this page’s job is only to say plainly that the option is real.

Infection prevention has PKD texture too: urinary infections are treated promptly and cultured properly because an ascending infection can seed a cyst, where ordinary antibiotics penetrate poorly and courses run long; women, who bear most urinary infections, are counselled on early treatment rather than watchful waiting; and instrumentation of the urinary tract happens under antibiotic cover. A treated bladder infection is trivial; a missed one that reaches a cyst can cost a hospital fortnight — the asymmetry that justifies the low threshold.

The foundations apply to everyone: blood pressure treated early and to target (RAS blockade first-line); the hydration, sodium, weight and avoidance rules above; prompt handling of the urological complications; standard CKD complication care as function declines; and — because a heritable, decades-long disease is also a psychological and family event — genetic counselling and honest prognosis conversations as part of care, not extras.

Tolvaptan is the era-marking addition: a vasopressin V2-receptor blocker that attacks the hormonal driver of cyst growth, shown in the TEMPO 3:4 and REPRISE trials to slow kidney volume growth and eGFR decline in rapidly progressing disease. It is licensed and guideline-recommended for exactly that fast lane (Mayo 1C–1E, steep slopes, high-risk profiles) — not for everyone — and it asks something of its takers: profound thirst and urine outputs that reorganise daily life around water and bathrooms, plus scheduled liver-enzyme monitoring for a rare hepatic reaction, under formal prescribing programmes. Many fast-lane patients judge the trade worthwhile; some do not; both are reasonable, and the drug’s existence has made measuring pace — volume MRI, Mayo classing — a practical necessity rather than an academic exercise. (Somatostatin analogues show volume effects, mainly hepatic, in selected settings; a genuine pipeline of further agents sits in trials, worth asking about in the fast lane.)

At kidney failure, ADPKD follows this platform’s standard replacement logic with PKD accents. Transplantation is the preferred destination and PKD patients are often excellent candidates — typically younger than the dialysis average, without diabetes, with strong post-transplant survival in registry after registry; pre-emptive living-donor transplant is the gold standard when family circumstances allow (related donors screened rigorously to exclude carrier status — imaging, and genetics where age leaves doubt). The PKD-specific question is the native kidneys: they are NOT routinely removed — nephrectomy adds surgical risk and loses residual urine output — but massive kidneys leaving no room for a graft, recurrent bleeding, chronic infection or intractable pain justify removal before, during or after transplant, a judgement individualised at experienced centres. Dialysis serves as bridge or destination as everywhere — haemodialysis commonly; peritoneal dialysis is feasible more often than the abdominal bulk suggests and is not automatically excluded.

Two lifestyle questions recur in every PKD clinic and deserve their honest answers here. Sport: fully encouraged, with a caveat only for high-impact contact sports where enlarged kidneys sit less protected — a judgement made on individual anatomy rather than a blanket ban. And water: the drink-to-suppress-vasopressin logic behind tolvaptan supports generous ordinary hydration for everyone with the disease — inexpensive, physiologically sensible, and the one intervention with no side-effect column, even if trials have not crowned it a therapy on its own.

ADPKD supplies transplant medicine with some of its most straightforward candidacies: patients who reach failure are, on average, younger and metabolically healthier than the dialysis population at large — no diabetes driving vascular disease, decades of anticipated benefit — and registry outcomes for PKD transplant recipients sit among the best of any diagnosis. The disease does not recur in the graft (the donor kidney lacks the variant), which removes a worry several other kidney diseases carry. Planning follows the standard arc this platform describes for kidney failure generally — evaluation from stage G4, pre-emptive listing or living donation as the ideal — with the additions PKD writes into the file.

The additions: native kidney assessment — is there ROOM for a graft, and are the native kidneys behaving? Most patients keep them; embolisation or nephrectomy (before, at, or after transplant, per centre philosophy) answers massive bulk, recurrent bleeding, chronic infection or unmanageable pain. Family-donor screening — a willing sibling or child must be cleared of ADPKD itself: imaging suffices at ages where criteria are definitive; genetic testing settles younger or equivocal cases, and no reputable programme skips this. Aneurysm review — many centres screen defined-risk candidates before major surgery. Liver assessment where polycystic liver is severe — the rare combined liver-kidney question belongs to specialised centres.

For international patients, PKD’s slow arithmetic is an organisational gift: failure is usually visible years ahead, which makes the well-prepared, pre-emptive, living-donor version of transplantation — the version with the best outcomes everywhere — genuinely achievable with foresight. The file a centre needs: the imaging history with volumes, eGFR slope, complication record (bleeds, infections, stones), blood pressure regimen, aneurysm screening status if done, and for any proposed related donor, the screening that proves they do not share the disease, plus the relationship documentation destination law requires. The pathway pages of this platform take the file from there — start with the kidney transplant and living donation guides, and end-stage renal disease for the failure stage.

The honest ADPKD outlook is a spread, not a sentence. At one end, PKD2 families and Mayo slow-lane patients may live full lives never needing dialysis; at the other, truncating-PKD1 fast-lane disease historically reached failure in the fifties — and it is precisely that end the modern toolkit targets. What has genuinely changed: hypertension treated from youth (with trial evidence for tighter targets in the young), the first disease-slowing drug in tolvaptan for those measured into the fast lane, complication care that has defanged most of the urological events, and — at failure — transplant outcomes that make ADPKD one of the better diagnoses to carry onto a transplant list. Registry survival for PKD transplant recipients, as the sources below document, leads most other kidney diagnoses; the disease’s non-recurrence in the graft and its patients’ typical fitness both contribute.

What the outlook asks of patients mirrors the disease’s tempo: decades of unglamorous consistency — blood pressure numbers kept, volumes measured, appointments held — punctuated by a handful of well-timed decisions (the tolvaptan choice when classed fast; the transplant preparation started at G4, not G5; the donor conversations had early). Prognostic precision, meanwhile, keeps improving: a patient today can carry a personalised forecast — genotype, Mayo class, slope — that their parent’s generation never had, and can plan careers, families and, where relevant, treatment abroad around it. For a disease once narrated as fated decline, that combination — measurable pace, a lever to slow it, and a strong exit option — is a quietly transformed story.

Family conversations are part of this disease’s management in a way few conditions share: each diagnosis implicates parents, siblings and children with mathematical precision, and households handle that differently — some test everyone early, some let each adult choose in their own time. Clinics increasingly host these conversations deliberately, with genetic counsellors present, because the evidence is clear that informed families screen better, control blood pressure earlier and reach transplant prepared. The disease runs in families; so, with a little structure, does its competent management.